Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Completed 16Terminated 7Active not recruiting 3Withdrawn 2Unknown 2Recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 1Polyps 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Radiotherapy 91pembrolizumab 88Cyclophosphamide 84Gemcitabine 70Cisplatin 70Magnetic Resonance Spectroscopy 65Carboplatin 60Radiosurgery 55Paclitaxel 55Nivolumab 48Dexamethasone 45Bevacizumab 42Biopsy 41Fluorouracil 39durvalumab 37Surveys and Questionnaires 36Docetaxel 36fludarabine 35Doxorubicin 35Radiation 33Oxaliplatin 33Capecitabine 33Rituximab 32fludarabine phosphate 31Leucovorin 31Cytarabine 30Melphalan 29Etoposide 28Pemetrexed 27Irinotecan 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × OTHER × Fatty Acids, Omega-3 × Clear all
NCT03661047 2021-11-17

OMICC

Massachusetts General Hospital

Phase 2 Withdrawn
Gastrointestinal

Colonic Neoplasms, Polyps, Colorectal Neoplasms

NCT00996749 2018-07-03

Omega-3 Fatty Acids in Treating Patients With Advanced Prostate Cancer

Wake Forest University Health Sciences

Phase NA Withdrawn
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡